4.3 Review

Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits

Lieske H. Schrijver et al.

Summary: In BRCA1 and BRCA2 mutation carriers, the use of combined-type oral contraceptive preparation (COCP) initially increases the risk of breast, ovarian, and endometrial cancer, but in the long term, it significantly decreases the lifetime cancer risk. Risk-reducing bilateral salpingo-oophorectomy and menopausal hormone therapy counteract the long-term benefits of COCP use.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Obstetrics & Gynecology

Menopausal Hormone Therapy Formulation and Breast Cancer Risk

Haim A. Abenhaim et al.

Summary: The use of menopausal hormone therapy (HT) is associated with an increased risk of breast cancer, particularly with formulations containing synthetic progestins. However, the use of bioidentical estrogens or animal-derived estrogens is not associated with breast cancer. When prescribing HT, micronized progesterone may be the safer option.

OBSTETRICS AND GYNECOLOGY (2022)

Article Obstetrics & Gynecology

The 2022 hormone therapy position statement of The North American Menopause Society

Stephanie S. Faubion et al.

Summary: The 2022 Hormone Therapy Position Statement of NAMS updates the previous statement and provides recommendations for the use of hormone therapy in menopausal women. Hormone therapy is effective in treating vasomotor symptoms and preventing bone loss, but its risks vary depending on individual factors. It is important to assess the benefits and risks on an individual basis and regularly reevaluate the need for continued therapy.

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2022)

Review Oncology

Beyond the pill: contraception and the prevention of hereditary ovarian cancer

Yue Yin Xia et al.

Summary: This article reviews the existing epidemiological evidence on the role of contraceptives in the risk of ovarian cancer, focusing on women with BRCA1 or BRCA2 mutations. The article discusses recent findings and gaps in knowledge, extrapolating from studies conducted among noncarrier populations.

HEREDITARY CANCER IN CLINICAL PRACTICE (2022)

Article Obstetrics & Gynecology

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

Lieske H. Schrijver et al.

Summary: The lack of treatments for obstetrical complications is mainly due to the challenges of drug development during pregnancy, requiring significant investments and commitment to research. Addressing this need requires collaboration from all stakeholders to advance effective and safe treatments for obstetrical syndromes.

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2021)

Article Oncology

Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium

Anna Morra et al.

Summary: Modifiable lifestyle factors such as BMI, smoking, physical activity, and age at first pregnancy are strongly associated with 10-year all-cause mortality among breast cancer patients. Associations were similar across different subtypes of breast cancer.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2021)

Review Oncology

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021

Mary B. Daly et al.

Summary: The NCCN Guidelines focus on assessing genetic variants associated with increased risk of breast, ovarian, and pancreatic cancer, particularly BRCA-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. Individuals with pathogenic BRCA1/2 variants have high risks of breast and ovarian cancer, as well as elevated risks of prostate cancer and pancreatic cancer. Li-Fraumeni syndrome is associated with high lifetime risks of various cancers.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Article Oncology

Trends in oral contraceptive and intrauterine device use among reproductive-aged women in the US from 1999 to 2017

Lauren A. King et al.

Summary: The use of intrauterine devices (IUDs) has been increasing more rapidly than the decline in oral contraceptive (OC) use among premenopausal US women, potentially reducing the risk of gynecologic cancer.

CANCER CAUSES & CONTROL (2021)

Review Endocrinology & Metabolism

Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery

Chrisandra L. Shufelt et al.

Summary: Menopausal hormone therapy has varying effects on cardiometabolic markers and cardiovascular disease risk depending on formulation, dose, and route of delivery. Oral estrogens without progestogens have positive effects on lipoprotein levels, glycemia, insulin, and CVD risk, while adding progestogens blunts the lipid-related effects. Transdermal estrogens have less impact on coagulation, inflammation, and lipids compared to oral estrogens, potentially posing a lower risk of venous thromboembolism and stroke.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Article Oncology

Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study

Marthe M. de Jonge et al.

Summary: This Dutch study showed that BRCA1/2 mutation carriers have a two- to threefold increased risk for endometrial cancer compared to the general population, with the highest risk observed in rare subgroups such as serous-like and p53-abnormal EC among BRCA1 mutation carriers.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Article Oncology

What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy

Martha Hickey et al.

Summary: Vasomotor symptoms increase within 3 months after RRSO, but do not worsen over the next 12 months. Hormone therapy can reduce but not completely resolve vasomotor symptoms, and may improve quality of life, but not to pre-oophorectomy levels.

GYNECOLOGIC ONCOLOGY (2021)

Review Obstetrics & Gynecology

Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis

Livia Conz et al.

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2020)

Article Obstetrics & Gynecology

Clinical Effects of Early or Surgical Menopause

Sheryl A. Kingsberg et al.

OBSTETRICS AND GYNECOLOGY (2020)

Article Primary Health Care

BRCA-Related Cancer Genetic Counseling is Indicated in Many Women Seeking Primary Care

Daniel J. Parente

JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE (2020)

Review Oncology

Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature

Nicole Birrer et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)

Editorial Material Medicine, General & Internal

Migraine Throughout the Female Reproductive Life Cycle

Stephanie S. Faubion et al.

MAYO CLINIC PROCEEDINGS (2018)

Article Obstetrics & Gynecology

Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting

Mark S. DeFrancesco et al.

OBSTETRICS AND GYNECOLOGY (2018)

Article Medicine, General & Internal

Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality The Women's Health Initiative Randomized Trials

Joann E. Manson et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Article Medicine, General & Internal

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Karoline B. Kuchenbaecker et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Article Medicine, General & Internal

Contemporary Hormonal Contraception and the Risk of Breast Cancer

Lina S. Morch et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Public, Environmental & Occupational Health

Exogenous Hormone Use: Oral Contraceptives, Postmenopausal Hormone Therapy, and Health Outcomes in the Nurses' Health Study

Shilpa N. Bhupathiraju et al.

AMERICAN JOURNAL OF PUBLIC HEALTH (2016)

Article Public, Environmental & Occupational Health

Youth Risk Behavior Surveillance - United States, 2015

Laura Kann et al.

MMWR SURVEILLANCE SUMMARIES (2016)

Article Public, Environmental & Occupational Health

US Medical Eligibility Criteria for Contraceptive Use, 2016

Kathryn M. Curtis et al.

MMWR RECOMMENDATIONS AND REPORTS (2016)

Article Public, Environmental & Occupational Health

Hormone Therapy and Young-Onset Breast Cancer

Katie M. O'Brien et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2015)

Article Oncology

Risk management options elected by women after testing positive for a BRCA mutation

Christine Garcia et al.

GYNECOLOGIC ONCOLOGY (2014)

Article Public, Environmental & Occupational Health

The Mortality Toll of Estrogen Avoidance: An Analysis of Excess Deaths Among Hysterectomized Women Aged 50 to 59 Years

Philip M. Sarrel et al.

AMERICAN JOURNAL OF PUBLIC HEALTH (2013)

Article Medicine, General & Internal

Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials

JoAnn E. Manson et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Article Obstetrics & Gynecology

Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study

William H. Parker et al.

OBSTETRICS AND GYNECOLOGY (2013)

Article Obstetrics & Gynecology

Premature menopause or early menopause and risk of ischemic stroke

Walter A. Rocca et al.

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2012)

Article Obstetrics & Gynecology

Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer

Juergen Dinger et al.

CONTRACEPTION (2011)

Article Medicine, General & Internal

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

Susan M. Domchek et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)

Article Multidisciplinary Sciences

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

Eva Gonzalez-Suarez et al.

NATURE (2010)

Article Obstetrics & Gynecology

Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study

William H. Parker et al.

OBSTETRICS AND GYNECOLOGY (2009)

Article Oncology

Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women

Rulla M. Tamimi et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)

Article Oncology

BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50

Robert W. Haile et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)

Article Obstetrics & Gynecology

Use of the levonorgestrel-releasing intrauterine system and breast cancer

T Backman et al.

OBSTETRICS AND GYNECOLOGY (2005)

Article Medicine, General & Internal

Breast cancer and hormone-replacement therapy in the Million Women Study

E Banks et al.

LANCET (2003)

Article Medicine, General & Internal

Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer

DM Gabrick et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)